Intelligo

Private limited company · Oslo

CALLUNA PHARMA AS

ActiveResearch and experimental development on natural sciences and engineering (72.100)

Founded
1 Sep 2023
Employees
9
Business address
Gaustadalléen 21, 0349 Oslo

The life line 2023–2026

Operating revenue per year, with recorded events above. As a table

Operating revenue 2025: NOK 36.3m.

  1. Kapital§ 14
  2. Managing director took office§ 07
  3. Founded§ 16

Sources: the Register of Company Accounts (company accounts), fetched 1 Nov 2026; the Brønnøysund Register Centre. Each event has the colour of the section it is in.

In brief

CALLUNA PHARMA AS is a private limited company in Oslo, founded in 2023, in the industry research and experimental development on natural sciences and engineering. The chief executive is Mark William-Semrau Gaffney, and the chair of the board is Mark Frederick Altmeyer. In 2025 the company had NOK 36.3m in operating revenue and a net profit of NOK −10.1m. The largest owner is CALLUNA PHARMA POOLCO AS with 34.9%.

Put together by Intelligo from the sections below; each figure stands with its source where it belongs.

Overview

§ 01 Latest changes

4 changes, latest 13 Nov 2026

  • Number of employees 10 → 9
  • Changed capital 104166995 → 123667000
  • Changed capital 1041669.95 → 1236670
  • New articles of association 11 Sep 2026

Source: the Brønnøysund Register Centre and Intelligo's own observations, fetched 15 Nov 2026 · All events →

Overview

§ 02 Worth knowing

2 points

  • NoteChanged auditor 5 Oct 2026
  • OKEquity ratio 83.9%, above the industry median

Assumed: derived by Intelligo by fixed rules, not a credit rating. How we calculate

Overview

§ 03 Key figures

Revenue NOK 36.3m in 2025

Revenue

NOK 36.3m

+35.1% from 2024

20232025

Operating profit

NOK −16.0m

+39.9% from 2024

20232025

Net profit

NOK −10.1m

+14.8% from 2024

20232025

Equity

NOK 1.1bn

+44.0% from 2024

20232025

Source: the Register of Company Accounts, read 1 Nov 2026 · The full accounts →

Finances

§ 04 Where the money comes from and goes

Financial year 2025

Of every krone of operating revenue in 2025:

  • Operating costs 144%

Costs exceeded revenue: the operating result was NOK −16.0m.

Source: the Register of Company Accounts, read 1 Nov 2026

Finances

§ 05 Financial health

Equity ratio 83.9%

RevenueNOK 36.3m Operating margin−44.0% Equity ratio83.9% Revenue growth+35.1%
  • CALLUNA PHARMA AS, 2025
  • Industry median, assumed: NOK 1.5m · −4.4% · 48.9% · +3.0%

Equity NOK 1.1bn84% of the assets (NOK 1.3bn)

Source: the Register of Company Accounts, read 1 Nov 2026. The median is derived by Intelligo from 694 companies in 72.100 Research and experimental development on natural sciences and engineering, not stated by the source.

Finances

§ 06 Accounts

2 years, latest 2025

NOK 1,0002024–2520252024
Operating revenue36,34426,905
Operating profit−16,004−26,638
Profit before tax−10,145−11,911
Net profit−10,145−11,911
Total assets1,319,877853,584
Equity1,107,692769,267
Liabilities212,18584,317

Source: the Register of Company Accounts, read 1 Nov 2026 · All 2 years →

Management and ownership

§ 07 Officers

10 officers now

The board: 6 members

Source: the Brønnøysund Register Centre, read 30 Oct 2026 · All 10 roles, former ones too →

Management and ownership

§ 08 Signature, procuration and authorisations

Styrets leder og ett styremedlem i fellesskap.

May sign for the company:

Styrets leder og ett styremedlem i fellesskap.

Procuration: none registered.

The board has 1 authorisation in force now: capital increase, until 23 May 2027.

The signature is word for word from the register. Source: the Register of Business Enterprises, read 5 Oct 2026

Management and ownership

§ 09 Owners

3 shareholders · largest 34.9%

OwnerShare
CALLUNA PHARMA POOLCO AS
34.9%
CALLUNA PHARMA POOLCO AS
0.7%
CALLUNA PHARMA POOLCO AS
0.4%

Source: the Tax Administration's Register of Shareholders as of 31 December 2025, read 30 Jul 2026 · All 3 owners →

Management and ownership

§ 10 Group

1 subsidiary

CALLUNA PHARMA AS parent company

Share held. Source: the Tax Administration's shareholder register, fetched 30 Jul 2026 · The whole group →

Management and ownership

§ 11 Portfolio

None registered

No holdings registered.The shareholder register has no shares held by the company. Checked 15 Nov 2026.

Management and ownership

§ 12 Network

11 connections

  • Person
  • Company

3 people link CALLUNA PHARMA AS to 9 other companies: Susanne Stuffers 4, Farzad Abdi-Dezfuli 3 and Mark William-Semrau Gaffney 2.

Source: the Brønnøysund Register Centre, read 30 Oct 2026 · Explore the network →

Events and registers

§ 13 Events

33 since 2023

Events per year

20232026

  • Notices28
  • Register changes5

Since 2023: 28 announcements and 5 register changes. Most happened in 2024 and 2026.

Source: the announcements of the Brønnøysund Register Centre, the Tax Administration's Register of Shareholders, Doffin, TED and NAV, read 2 Nov 2026. Register changes are Intelligo's own observations. · All 33 events →

Events and registers

§ 14 Notices

28, latest 28 Oct 2026

  • Kapital
  • Vedtektsdato
  • Revisor

Source: The Brønnøysund Register Centre's announcements ↗, read 2 Nov 2026 · All 28 →

Events and registers

§ 15 Charges

Not fetched yet

Events and registers

§ 16 Other registers

Found in 3 of 7

  • The Central Coordinating RegisterRegistered 14 Oct 2023
  • VATRegistered
  • The Register of Business EnterprisesRegistered 14 Oct 2023
  • The Cleaning RegisterNot registered
  • The Register of Staffing AgenciesNot registered
  • Smiley scheme, the Norwegian Food Safety AuthorityNot registered
  • The Financial Supervisory Authority's licence registerNot registered

Purpose: Å investere i farmasøytiske selskaper og virksomheter, herunder å realisere slike investeringer, samt all annen virksomhet knyttet til dette.

Source: the Brønnøysund Register Centre, the Labour Inspection Authority, the Food Safety Authority and the Financial Supervisory Authority, each on its own, fetched 15 Nov 2026

Market

§ 17 Tenders

None registered

No tenders recorded.No public tenders won, lost or announced, in Doffin or TED. Checked 15 Nov 2026.

Market

§ 18 Vacancies

None registered

No vacancies.No open ads at NAV. Checked 15 Nov 2026.

Market

§ 19 Competitors

Industry code 72.100

The companies most like it:

Compare them

The selection is Intelligo's, not stated by the source: companies met in tenders and winners of tenders of the same kind, otherwise the same industry code, nearest in place and size. Source: the Brønnøysund Register Centre, Doffin and TED, fetched 15 Nov 2026 · All competitors → · Largest in the industry →

Last

§ 20 Questions and answers

7 questions

  • Who is the chief executive of CALLUNA PHARMA AS?
    Mark William-Semrau Gaffney, since 2024. § 07
  • Who owns CALLUNA PHARMA AS?
    3 shareholders. The largest is CALLUNA PHARMA POOLCO AS with 34.9%, CALLUNA PHARMA POOLCO AS with 0.7% and CALLUNA PHARMA POOLCO AS with 0.4%. § 09
  • What was the revenue in 2025?
    NOK 36.3m in the company. § 06
  • Who can sign for CALLUNA PHARMA AS?
    Styrets leder og ett styremedlem i fellesskap. § 08
  • Who is the auditor?
    PRICEWATERHOUSECOOPERS AS, from 5 Oct 2026. § 07
  • Where is CALLUNA PHARMA AS based?
    Gaustadalléen 21, 0349 Oslo.
  • When was CALLUNA PHARMA AS founded?
    1 Sep 2023, registered in the Register of Business Enterprises 14 Oct 2023. § 16

The answers come from the sections linked to, with their sources.

01Latest changesOverviewContentsClose